Results 41 to 50 of about 1,763,205 (168)
Neuropsychiatric Adverse Events Associated With Foslevodopa/Foscarbidopa Continuous Subcutaneous Infusion in Clinical Practice: A Multicenter Study
European Journal of Neurology, Volume 33, Issue 7, July 2026.In 214 patients with advanced Parkinson's disease receiving foslevodopa/foscarbidopa continuous subcutaneous infusion, neuropsychiatric adverse events occurred in 19.2%. Baseline cognitive impairment and hallucinations did not increase risk, whereas preexisting impulse control disorders predicted ICD‐related adverse events.David Campo‐Caballero, Jon Rodriguez‐Antiguedad, Arnau Puig‐Davi, Javier Ruiz‐Martinez, Ana Vinagre‐Aragón, Elisabet Mondragón, Lara Pardina Vilella, Nuria López‐Ariztegui, Nuria Caballol, Guillermo González‐Ortega, Iria Cabo, Rocío García Ramos, Inés Legarda, Marta Blázquez‐Estrada, Pilar Sánchez‐Alonso, Pablo Mir, Juan Carlos Romero Fábrega, Silvia Martí Martinez, María Álvarez Sauco, Diego Santos‐García, DATs‐PD GETM Spanish Registry Group, Nuria López Ariztegui, Maria Isabel Morales Casado, Guillermo Tabar Comellas, Asunción Ávila Rivera, Núria Caballol Pons, Anna Planas‐Ballvé, Alejandro Peral Quirós, Dolors Lozano, Diego Santos García, Jose Manuel Paz González, Carlos Cores Bartolomé, Lucia Belen Samaniego Vinueza, Ángela Solleiro Vidal, Iria Cabo, Alejandro Rivero de Aguilar Pensado, Rocío García Ramos, Ana Fernández Revuelta, Eva López Valdés, Ana Aldaz, Carmen Ribacoba Díaz, Inés Legarda Ramírez, Bàrbara Vives Pastor, María Fuensanta Valero García, Marta Blázquez Estrada, Esther Suárez San Martín, Ciara García Fernández, Pilar Tartiere, Patricia Prendes Fernández, Pilar Sánchez‐Alonso, Sabela Novo Ponte, Elisa Gamo González, Raquel Martín García, Pablo Mir Rivera, Laura Muñoz Delgado, Astrid Daniela Adarmes Gómez, Elena Ojeda Lepe, Silvia Jesús Maestre, Daniel Macías García, Fátima Carrillo García, Ana María Castellano Guerrero, Manuela San Eufrasio Martínez, Cristina Pérez Calvo, María López González, Andrés García Herruzo, Cristina Gómez Rapela, Lorena Garrote Espina, Natalia González Rojas, Juan Carlos Romero Fábrega, Francisco Escamilla Sevilla, Lucía Triguero Cueva, Carlos Javier Madrid Navarro, Silvia Martí Martínez, María Álvarez Sauco, Eric Freire Álvarez, Jessica González Ardura, Belén Castaño García, Antonio Sánchez Rodríguez, Déborah Alonso Modino, Jesús Norelis Lorenzo Brito, Maria Esther Rojas Pérez, Carolina Hernández Javier, Jorge Hernández Vara, Maria Victoria González, Sara Belmonte, Débora María Cerdán Santacruz, Amelia Mendoza Rodríguez, Ana Castrillo Sanz, Lorena Caballero Sánchez, Claudia Gómez López de San Román, Álvaro Sánchez‐Ferro, Pablo Rábano Suárez, Antonio Méndez Guerrero, Daniel Pérez Rangel, Jesús Ramírez, Cristina del Álamo Criado, Javier Ruíz Martínez, Elisabet Mondragón Rezola, Ana Vinagre Aragón, Lara Pardina Vilella, David Campo Caballero, Ana Belén Perona Moratalla, Gustavo Fernández‐Pajarín, Maria Pilar Gil Villar, Agustín Sancho Saldana, Laura Quibus Requena, Ángela Monterde Ortega, Juan Carlos Gómez Esteban, Tamara Fernández Valle, Marta Ruiz López, Beatriz Tijero Merino, Susana Cantarero Duque, Guillermo González‐Ortega, Esther Cubo Delgado, Beatriz Alegre García, Lydia López Manzanares, Inés Muro, Elena Casas Peña, Pablo Lorenzo Barreto, Emma Cañada Lahoz, Sara Lozano Veiga, Lydia Vela, Irene Martínez‐Torres, Carlos Morata‐Martínez, Raquel Baviera‐Muñoz, Marina Campins Romeu, Isabel Sastre Bataller, Elena Navarro Mocholí, Roberto López Blanco, Sonia Escalante Arroyo, Tania Delgado Ballestero +130 morewiley +1 more sourceA Sequence‐Based Update on Amino Acid Substitutions in Influenza Polymerase Acidic Protein in Europe That Alter Baloxavir Susceptibility From 2009 to 2025
Influenza and Other Respiratory Viruses, Volume 20, Issue 7, July 2026.ABSTRACT Background
Influenza causes 650,000 deaths, 3–5 million hospitalizations, and 1 billion cases worldwide each year. There is a limited repertoire of antivirals available to tackle this burden, highlighting the risk of developing resistance to current drugs.Alejandro Martín‐Toribio, Inés Inchausti‐Moya, Marina Toquero‐Asensio, Sonia García‐Díaz, Javier Sanchez‐Martinez, Carla Rodriguez‐Crespo, Silvia Galindo‐Carretero, Raquel Iglesia‐Aparicio, Celia Lopez‐Gonzalo, Ana Antón‐Contreras, Silvia Rojo‐Rello, Marta Dominguez‐Gil, Marta Hernández, Jose M. Eiros, Estanislao Nistal‐Villan, Iván Sanz‐Muñoz +15 morewiley +1 more sourceCharacteristics and Risk Factors Associated With Hospitalization and Severe Disease in Patients Aged ≥ 60 Years With Human Metapneumovirus Infection Over Three Consecutive Seasons (2021–2024) in Valladolid, Spain. The VALLAVIRUS Study
Influenza and Other Respiratory Viruses, Volume 20, Issue 7, July 2026.ABSTRACT Background
Human metapneumovirus (hMPV) is a respiratory pathogen often underestimated in the elderly. Although studies suggest it causes around 10% of respiratory hospitalizations in the United States, national and local data remain scarce.Iván Sanz‐Muñoz, Silvia Galindo‐Carretero, Marina Toquero‐Asensio, Alejandro Martín‐Toribio, Raquel Iglesia‐Aparicio, Celia López‐Gonzalo, Diana Rodríguez‐González, Laura Tamayo‐Pérez, Javier Sánchez‐Martínez, Carla Rodríguez‐Crespo, Alberto Caballero‐García, Marta Domínguez‐Gil, Silvia Rojo‐Rello, José María Eiros +13 morewiley +1 more sourceIncidence, Complications, and Quality of Life in Adults ≥ 60 Years Old With Laboratory‐Confirmed RSV Infections Attended in Primary Care and in Hospitals: A Study Over Three Seasons in Valladolid, Spain
Influenza and Other Respiratory Viruses, Volume 20, Issue 7, July 2026.ABSTRACT Background
Respiratory syncytial virus (RSV) infection in adults ≥ 60 years significantly affects health, particularly in those with comorbidities. Despite evidence on disease burden, data on quality of life (QoL) and complications after infection remain scarce.Iván Sanz‐Muñoz, Raquel Iglesia‐Aparicio, Celia López‐Gonzalo, Marina Toquero‐Asensio, Alejandro Martín‐Toribio, Javier Sánchez‐Martínez, Carla Rodríguez‐Crespo, Irene Arroyo‐Hernantes, Silvia Galindo‐Carretero, Leticia Sierra‐Martínez, José Francisco Pérez‐Pertejo, Gregoria Núñez‐Villareal, Raquel Rodríguez‐García, Rosario Fernández‐Gonzalez, Oscar Hugo Martín‐Del Barco, Ana María Fernández‐Herrero, Inmaculada Alarcia‐Santana, Alicia Gómez‐Muñoz, Cristina Alonso‐Estomba, Ana Asenjo‐Martín, Gemma Renedo‐Velasco, Marta Moral‐Blanco, José Gabriel Muñoz‐Hernández, Oscar Vega‐Hernández, Myriam Rodríguez‐Calleja, María del Mar Gonzalo‐Fernandez, Rachel Melanie Reeves, Abda Mahmood, Lucia Izquierdo‐Díaz, Elisa Turriani, Virginia Fernández‐Espinilla, Cristina Hernán‐García, Javier Castrodeza‐Sanz, Virginia Cerpa‐Almenara, Javier Gutiérrez‐Ballesteros, Laura Iotti, Marta Domínguez‐Gil, Silvia Rojo‐Rello, José María Eiros +38 morewiley +1 more sourceEstudios clínicos con inhibidores de la PCSK9
Revista Colombiana de Cardiología, 2017 Los inhibidores de la enzima proproteína convertasa subtilisina kexina tipo 9 (PCSK9) constituyen una herramienta terapéutica novedosa para el selecto grupo de pacientes de muy alto riesgo en quienes no se han alcanzado las metas de colesterol LDL.Rafael Campodoaj +1 more source